[HTML][HTML] Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

Y Li, Y Liu, S Liu, M Gao, W Wang, K Chen… - Signal transduction and …, 2023 - nature.com
Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Update on the pathophysiology and medical treatment of peripheral artery disease

J Golledge - Nature reviews cardiology, 2022 - nature.com
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower
limb arteries (peripheral artery disease (PAD)) and the prevalence is rising. PAD causes leg …

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …

G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Rivaroxaban in peripheral artery disease after revascularization

MP Bonaca, RM Bauersachs, SS Anand… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …

Advances in revascularization for peripheral artery disease: revascularization in PAD

JA Beckman, PA Schneider, MS Conte - Circulation research, 2021 - Am Heart Assoc
Effective revascularization of the patient with peripheral artery disease is about more than
the procedure. The approach to the patient with symptom-limiting intermittent claudication or …

Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular …

V Aboyans, R Bauersachs, L Mazzolai… - European Heart …, 2021 - academic.oup.com
The aim of this collaborative document is to provide an update for clinicians on best
antithrombotic strategies in patients with aortic and/or peripheral arterial diseases …

Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial

AS De Vriese, R Caluwé… - Journal of the …, 2021 - journals.lww.com
Background In patients with normal renal function or early stage CKD, the risk-benefit profile
of direct oral anticoagulants (DOACs) is superior to that of vitamin K antagonists (VKAs). In …

Contemporary medical management of peripheral artery disease

MP Bonaca, NM Hamburg, MA Creager - Circulation research, 2021 - Am Heart Assoc
Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable
risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity …

[PDF][PDF] 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …

M Brunström, M Burnier… - Journal of …, 2023 - docred-strapi-cms-prod.s3.sa-east-1 …
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The …

KAA Fox, V Aboyans, ES Debus… - European Heart …, 2022 - academic.oup.com
Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …